Stock DNA
Pharmaceuticals & Biotechnology
CNY 6,536 Million (Mid Cap)
40.00
NA
1.40%
-0.23
6.61%
1.86
Revenue and Profits:
Net Sales:
172 Million
(Quarterly Results - Mar 2026)
Net Profit:
27 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-16.91%
0%
-16.91%
6 Months
-27.97%
0%
-27.97%
1 Year
9.9%
0%
9.9%
2 Years
-7.37%
0%
-7.37%
3 Years
-31.18%
0%
-31.18%
4 Years
-51.89%
0%
-51.89%
5 Years
-85.41%
0%
-85.41%
Chengdu Kanghua Biological Products Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
2.15%
EBIT Growth (5y)
-12.36%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.22
Sales to Capital Employed (avg)
0.40
Tax Ratio
14.30%
Dividend Payout Ratio
33.03%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
28.87%
ROE (avg)
16.97%
Valuation key factors
Factor
Value
P/E Ratio
40
Industry P/E
Price to Book Value
2.93
EV to EBIT
33.64
EV to EBITDA
27.00
EV to Capital Employed
3.43
EV to Sales
8.01
PEG Ratio
NA
Dividend Yield
0.91%
ROCE (Latest)
10.19%
ROE (Latest)
7.30%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY
Mar'26
Mar'25
Change(%)
Net Sales
172.50
137.40
25.55%
Operating Profit (PBDIT) excl Other Income
25.80
39.90
-35.34%
Interest
0.30
1.10
-72.73%
Exceptional Items
1.90
0.10
1,800.00%
Consolidate Net Profit
27.40
20.70
32.37%
Operating Profit Margin (Excl OI)
149.40%
136.90%
1.25%
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2026 is 25.55% vs -55.66% in Mar 2025
Consolidated Net Profit
YoY Growth in quarter ended Mar 2026 is 32.37% vs -86.15% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
1,160.70
1,421.60
-18.35%
Operating Profit (PBDIT) excl Other Income
334.30
591.10
-43.44%
Interest
3.70
5.40
-31.48%
Exceptional Items
-3.70
-59.70
93.80%
Consolidate Net Profit
219.90
398.70
-44.85%
Operating Profit Margin (Excl OI)
211.70%
363.30%
-15.16%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -18.35% vs -9.31% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -44.85% vs -21.70% in Dec 2024
About Chengdu Kanghua Biological Products Co., Ltd. 
Chengdu Kanghua Biological Products Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






